register

News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) PharmaQC to Thermo Fisher Scientific. This milestone marks a noteworthy achievement for the company, showcasing its expansion in the medical technology sector.

The potential benefits of the system is substantial, with the promise of streamlining quality control processes and improving the reliability and safety of pharmaceutical products. The move follows a surge in market interest from pharmaceutical customers, a testament to the success of LBT Innovations’ market development activities undertaken in the latter half of the calendar year 2023. Notably, this accomplishment comes approximately six months ahead of initial expectations.

What sets APAS PharmaQC apart is its distinction as the sole artificial intelligence technology for automated culture plate reading to have received clearance from the United States Food and Drug Administration (FDA).

As part of a strategic development partnership with Thermo Fisher, LBT Innovations finalised the sale of the instrument, providing essential funding for the ongoing development of APAS PharmaQC. The system is designed to support culture plate media utilised in pharmaceutical microbial quality control applications.

Brent Barnes, CEO and Managing Director of LBT Innovations, expressed the significance of this achievement, stating, “This is an important milestone for the Company, being the first deployment of APAS PharmaQC outside of our partnership with AstraZeneca. The evaluation performed by Thermo Fisher will provide meaningful performance data supporting ‘real-world’ use of our technology. This will provide a further third-party validation of APAS PharmaQC and further enhance our commercial activation of the product.”

The company’s focus on research and development has received backing from MTPConnect through the BioMedTech Horizons (BMTH) accelerator program. This support plays a crucial role in transforming innovative ideas into tangible, homegrown medical products, contributing to the development of critical sovereign manufacturing capabilities.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Parliament passes lung cancer legislation

Parliament passes lung cancer legislation

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Lung cancer is the leading cause of cancer death and is responsible for almost one in […]

More


News & Trends - Pharmaceuticals

Senator Ruston criticises Budget's lack of 'real seamanship' in tackling pressing healthcare challenges

Senator Ruston criticises Budget’s lack of ‘real seamanship’ in tackling pressing healthcare challenges

Health Industry Hub | May 17, 2024 |

Pharma News: Senator Anne Ruston, Shadow Health Minister, was warmly welcomed at the Post-Budget event held in Parliament House yesterday […]

More


News & Trends - MedTech & Diagnostics

Baxter announces branding for spin-off kidney care business

Baxter announces branding for spin-off kidney care business

Health Industry Hub | May 17, 2024 |

MedTech & Diagnostics News: Baxter has unveiled the mission and logo for its forthcoming kidney care and acute therapies company, […]

More


ESG

Health and climate strategy: All talk, no budget

Health and climate strategy: All talk, no budget

Health Industry Hub | May 16, 2024 |

ESG: The Federal Budget has sparked disappointment among health professionals for its lack of attention to addressing the escalating impacts […]

More


This content is copyright protected. Please subscribe to gain access.